|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
EP2892924B1
(en)
*
|
2012-06-14 |
2020-11-25 |
Therapix Biosciences Ltd. |
Humanized antibodies to cluster of differentiation 3 (cd3)
|
|
CN105283201B
(zh)
|
2013-03-14 |
2019-08-02 |
斯克利普斯研究所 |
靶向剂抗体偶联物及其用途
|
|
CN105722859B
(zh)
*
|
2013-07-25 |
2021-05-07 |
西托姆克斯治疗公司 |
多特异性抗体、多特异性可活化抗体及其使用方法
|
|
NZ718283A
(en)
|
2013-09-25 |
2022-05-27 |
Cytomx Therapeutics Inc |
Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
|
|
IL263466B2
(en)
|
2013-12-17 |
2023-10-01 |
Genentech Inc |
Anti-CD3 antibodies and methods of using them
|
|
US9562073B2
(en)
|
2014-01-31 |
2017-02-07 |
Cytomx Therapeutics, Inc. |
Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
|
|
CA2955947A1
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
PT3221356T
(pt)
|
2014-11-20 |
2020-10-29 |
Hoffmann La Roche |
Moléculas de ligação ao antigénio biespecíficas ativadoras das células t contra folr1 e cd3
|
|
DK3221357T3
(da)
|
2014-11-20 |
2020-08-10 |
Hoffmann La Roche |
Fælles letkæder og fremgangsmåder til anvendelse
|
|
MA41374A
(fr)
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
|
EP3296395B2
(en)
|
2015-05-13 |
2024-06-19 |
Chugai Seiyaku Kabushiki Kaisha |
Multiple antigen binding molecular fusion, pharmaceutical composition, method for identifying linear epitope, and method for preparing multiple antigen binding molecular fusion
|
|
US9708412B2
(en)
|
2015-05-21 |
2017-07-18 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
MX383464B
(es)
*
|
2015-07-13 |
2025-03-14 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
|
MX2018005232A
(es)
*
|
2015-11-03 |
2018-08-15 |
Ambrx Inc |
Anticuerpos anti-cd3 novedosos y sus usos.
|
|
FI3377103T4
(fi)
|
2015-11-19 |
2025-04-16 |
Revitope Limited |
Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten
|
|
IL313608A
(en)
|
2015-12-09 |
2024-08-01 |
Hoffmann La Roche |
Antibody against CD20 type II to reduce the formation of antibodies against drugs
|
|
KR102891788B1
(ko)
*
|
2016-02-04 |
2025-11-26 |
더 스크립스 리서치 인스티튜트 |
인간화 항-cd3 항체, 접합체 및 이의 용도
|
|
WO2017143259A1
(en)
*
|
2016-02-19 |
2017-08-24 |
Dignity Health |
Antibody fusion protein and related compositions for targeting cancer
|
|
US12128102B2
(en)
|
2016-03-08 |
2024-10-29 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
WO2017162587A1
(en)
*
|
2016-03-22 |
2017-09-28 |
F. Hoffmann-La Roche Ag |
Protease-activated t cell bispecific molecules
|
|
JP7015244B2
(ja)
*
|
2016-03-22 |
2022-02-02 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
プロテアーゼ活性化t細胞二重特異性分子
|
|
PT3433273T
(pt)
|
2016-03-25 |
2022-02-21 |
Biomunex Pharmaceuticals |
Moléculas de ligação a cd38 e pd-l1
|
|
SG11201809316XA
(en)
|
2016-04-28 |
2018-11-29 |
Biomunex Pharmaceuticals |
Bispecific antibodies targeting egfr and her2
|
|
EP3493844A4
(en)
|
2016-05-20 |
2021-03-24 |
Harpoon Therapeutics Inc. |
SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
WO2018220099A1
(en)
|
2017-06-02 |
2018-12-06 |
F. Hoffmann-La Roche Ag |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
RU2769282C2
(ru)
|
2016-06-20 |
2022-03-30 |
Кимаб Лимитед |
Анти-PD-L1 и IL-2 цитокины
|
|
WO2018004338A1
(en)
|
2016-06-27 |
2018-01-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
|
CN109843327B
(zh)
|
2016-07-07 |
2022-05-13 |
小利兰·斯坦福大学托管委员会 |
抗体佐剂缀合物
|
|
PE20241349A1
(es)
*
|
2016-09-14 |
2024-07-03 |
Teneobio Inc |
Anticuerpos de union a cd3
|
|
CN106632681B
(zh)
*
|
2016-10-11 |
2017-11-14 |
北京东方百泰生物科技有限公司 |
抗egfr和抗cd3双特异抗体及其应用
|
|
MY200695A
(en)
*
|
2016-11-03 |
2024-01-11 |
Bristol Myers Squibb Co |
Activatable anti-ctla-4 antibodies and uses thereof
|
|
JP7784795B2
(ja)
|
2016-11-15 |
2025-12-12 |
ジェネンテック, インコーポレイテッド |
抗cd20/抗cd3二重特異性抗体による処置のための投与
|
|
JP7626577B2
(ja)
|
2016-11-28 |
2025-02-07 |
中外製薬株式会社 |
リガンド結合活性が調整可能なリガンド結合分子
|
|
BR112019008727A2
(pt)
|
2016-11-28 |
2019-07-16 |
Chugai Seiyaku Kabushiki Kaisha |
domínio de ligação ao antígeno, e polipeptídeo incluindo seção de transporte
|
|
WO2018106945A1
(en)
|
2016-12-07 |
2018-06-14 |
Progenity Inc. |
Gastrointestinal tract detection methods, devices and systems
|
|
WO2018108759A1
(en)
|
2016-12-13 |
2018-06-21 |
F. Hoffmann-La Roche Ag |
Method to determine the presence of a target antigen in a tumor sample
|
|
IL317134A
(en)
|
2016-12-21 |
2025-01-01 |
Teneobio Inc |
An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
|
|
AU2018225164A1
(en)
*
|
2017-02-22 |
2019-09-19 |
Aleta Biotherapeutics Inc. |
Compositions and methods for treatment of cancer
|
|
US10093731B2
(en)
|
2017-02-24 |
2018-10-09 |
Kindred Biosciences, Inc. |
Anti-IL31 antibodies for veterinary use
|
|
KR20240125061A
(ko)
|
2017-03-27 |
2024-08-19 |
바이오뮤넥스 파마슈티컬스 |
안정적인 다중특이적 항체
|
|
WO2018183929A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
|
SG11201909160WA
(en)
|
2017-04-11 |
2019-10-30 |
Inhibrx Inc |
Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
|
|
EP3409322A1
(en)
|
2017-06-01 |
2018-12-05 |
F. Hoffmann-La Roche AG |
Treatment method
|
|
EP3634998B8
(en)
*
|
2017-06-05 |
2025-04-09 |
Numab Therapeutics AG |
Anti-cd3 epsilon antibodies
|
|
WO2018224441A1
(en)
*
|
2017-06-05 |
2018-12-13 |
Numab Innovation Ag |
Novel anti-cd3 antibodies
|
|
KR20250007003A
(ko)
|
2017-06-20 |
2025-01-13 |
테네오바이오, 인코포레이티드 |
항-bcma 중쇄-단독 항체
|
|
CN110945026B
(zh)
|
2017-06-20 |
2024-03-19 |
特纳奥尼股份有限公司 |
仅有重链的抗bcma抗体
|
|
EP3645050A4
(en)
*
|
2017-06-25 |
2021-08-11 |
Systimmune, Inc. |
Multi-specific antibodies and methods of making and using thereof
|
|
JP2020530554A
(ja)
*
|
2017-07-20 |
2020-10-22 |
シートムエックス セラピューティクス,インコーポレイテッド |
活性化抗体の特性を定性的および/または定量的に分析する方法およびその使用
|
|
WO2019036855A1
(en)
|
2017-08-21 |
2019-02-28 |
Adagene Inc. |
Anti-cd137 molecules and use thereof
|
|
JP7164596B2
(ja)
*
|
2017-08-28 |
2022-11-01 |
システィミューン, インク. |
抗cd3抗体とその作製及び使用方法
|
|
CN110799546B
(zh)
*
|
2017-09-01 |
2023-01-24 |
四川科伦博泰生物医药股份有限公司 |
重组双特异性抗体
|
|
CN111356700A
(zh)
|
2017-09-08 |
2020-06-30 |
马弗里克治疗公司 |
受约束的条件性活化的结合蛋白
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
MX2020003915A
(es)
|
2017-10-13 |
2020-10-08 |
Harpoon Therapeutics Inc |
Proteinas trispecificas y metodos de uso.
|
|
EP3694885A1
(en)
*
|
2017-10-14 |
2020-08-19 |
CytomX Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
TWI880235B
(zh)
|
2017-11-28 |
2025-04-11 |
日商中外製藥股份有限公司 |
可調整配體結合活性的配體結合分子
|
|
JP7482630B2
(ja)
|
2017-11-28 |
2024-05-14 |
中外製薬株式会社 |
抗原結合ドメインおよび運搬部分を含むポリペプチド
|
|
CN111683966B
(zh)
|
2017-12-22 |
2023-07-11 |
特尼奥生物股份有限公司 |
与cd22结合的重链抗体
|
|
CN107880129B
(zh)
*
|
2017-12-28 |
2021-01-15 |
广州市鲁诚生物科技有限公司 |
一种重组抗体及其制备方法
|
|
WO2019148445A1
(en)
*
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
WO2019148444A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Anti-ctla4 antibodies and methods of making and using the same
|
|
JP7337079B2
(ja)
*
|
2018-02-15 |
2023-09-01 |
マクロジェニクス,インコーポレーテッド |
変異型cd3結合ドメイン、及び疾患の治療のための併用療法におけるその使用
|
|
JP2021518603A
(ja)
|
2018-03-20 |
2021-08-02 |
シートムエックス セラピューティクス,インコーポレイテッド |
哺乳動物対象における活性化可能抗体種の定量薬理学モデリングのためのシステムおよび方法
|
|
CN110305217B
(zh)
|
2018-03-27 |
2022-03-29 |
广州爱思迈生物医药科技有限公司 |
双特异性抗体及其应用
|
|
KR20260046525A
(ko)
|
2018-04-11 |
2026-04-07 |
인히브릭스 바이오사이언스, 인크. |
제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
|
|
WO2019213444A1
(en)
|
2018-05-02 |
2019-11-07 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
AU2019271148B9
(en)
|
2018-05-14 |
2025-05-29 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
|
WO2019222296A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
|
US12534734B2
(en)
*
|
2018-05-15 |
2026-01-27 |
Drive Therapeutics Llc |
Stem-loop compositions and methods for inhibiting interleukin-8
|
|
KR102602329B1
(ko)
*
|
2018-05-23 |
2023-11-16 |
화이자 인코포레이티드 |
Cd3에 특이적인 항체 및 이의 용도
|
|
US20210253672A1
(en)
|
2018-05-30 |
2021-08-19 |
Chugai Seiyaku Kabushiki Kaisha |
Ligand-binding molecule containing single domain antibody
|
|
JP7414736B2
(ja)
|
2018-05-30 |
2024-01-16 |
中外製薬株式会社 |
アグリカン結合ドメインおよび運搬部分を含むポリペプチド
|
|
US12168691B2
(en)
|
2018-05-31 |
2024-12-17 |
Board Of Regents, The University Of Texas System |
VHS format bi-specific antibodies specific for HER2 and VEGF and use thereof
|
|
TWI848953B
(zh)
*
|
2018-06-09 |
2024-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
|
WO2019241216A1
(en)
*
|
2018-06-14 |
2019-12-19 |
Bioatla, Llc |
Multi-specific antibody constructs
|
|
WO2019246317A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue originating from the endoderm
|
|
WO2019246312A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
|
TW202016144A
(zh)
*
|
2018-06-21 |
2020-05-01 |
日商第一三共股份有限公司 |
包括cd3抗原結合片段之組成物及其用途
|
|
EP3827019A1
(en)
|
2018-07-24 |
2021-06-02 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
SG11202013248YA
(en)
|
2018-07-31 |
2021-02-25 |
Amgen Inc |
Pharmaceutical formulations of masked antibodies
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
US10815311B2
(en)
|
2018-09-25 |
2020-10-27 |
Harpoon Therapeutics, Inc. |
DLL3 binding proteins and methods of use
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
JP2022504802A
(ja)
|
2018-10-11 |
2022-01-13 |
インヒブルクス インコーポレイテッド |
5t4シングルドメイン抗体およびその治療組成物
|
|
JP7611820B2
(ja)
|
2018-10-11 |
2025-01-10 |
インヒブルクス バイオサイエンシズ インコーポレイテッド |
Dll3シングルドメイン抗体およびその治療用組成物
|
|
CN113166261A
(zh)
|
2018-10-11 |
2021-07-23 |
印希比股份有限公司 |
B7h3单域抗体及其治疗性组合物
|
|
CN120623346A
(zh)
|
2018-10-11 |
2025-09-12 |
因荷布瑞克斯生物科学公司 |
Pd-1单结构域抗体及其治疗组合物
|
|
SMT202400519T1
(it)
|
2018-11-12 |
2025-01-14 |
Debiopharm Int Sa |
Composti antibiotici. metodi di produzione degli stessi, composizioni farmaceutiche contenenti gli stessi e loro usi
|
|
EP3883635A1
(en)
|
2018-11-19 |
2021-09-29 |
Progenity, Inc. |
Methods and devices for treating a disease with biotherapeutics
|
|
CA3120327A1
(en)
|
2018-12-06 |
2020-06-11 |
Cytomx Therapeutics, Inc. |
Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
|
|
CN112703013B
(zh)
*
|
2019-02-22 |
2022-09-30 |
武汉友芝友生物制药股份有限公司 |
Cd3抗原结合片段及其应用
|
|
EP4592313A3
(en)
|
2019-03-05 |
2025-11-19 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
WO2020190725A1
(en)
|
2019-03-15 |
2020-09-24 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting her2
|
|
WO2020206330A1
(en)
|
2019-04-05 |
2020-10-08 |
Teneobio, Inc. |
Heavy chain antibodies binding to psma
|
|
CN113811546B
(zh)
*
|
2019-05-07 |
2025-03-11 |
免疫里森公司 |
前体三特异性抗体构建体及其使用方法
|
|
EP3969035A4
(en)
|
2019-05-14 |
2023-06-21 |
Werewolf Therapeutics, Inc. |
SEPARATION UNITS AND METHODS AND THEIR USE
|
|
JP7489407B2
(ja)
|
2019-05-21 |
2024-05-23 |
ノバルティス アーゲー |
Cd19結合分子及びその使用
|
|
WO2020246563A1
(ja)
|
2019-06-05 |
2020-12-10 |
中外製薬株式会社 |
抗体切断部位結合分子
|
|
JP2022535924A
(ja)
*
|
2019-06-06 |
2022-08-10 |
ジャナックス セラピューティクス,インク. |
腫瘍活性化t細胞エンゲージャーに関する組成物および方法
|
|
CR20210622A
(es)
|
2019-06-14 |
2022-06-27 |
Teneobio Inc |
Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
|
|
CA3143519A1
(en)
*
|
2019-06-26 |
2020-12-30 |
Volker Schellenberger |
Cd3 antigen binding fragments and compositions comprising same
|
|
JP6881658B2
(ja)
|
2019-07-05 |
2021-06-02 |
小野薬品工業株式会社 |
Pd−1/cd3二重特異性タンパク質による血液がん治療
|
|
GB201912681D0
(en)
*
|
2019-09-04 |
2019-10-16 |
Eth Zuerich |
Bispecific binding agent that binds to cd117/c-kit and cd3
|
|
WO2021053587A1
(en)
|
2019-09-18 |
2021-03-25 |
Klaus Strein |
Bispecific antibodies against ceacam5 and cd3
|
|
JP2022548310A
(ja)
*
|
2019-09-23 |
2022-11-17 |
シートムエックス セラピューティクス,インコーポレイテッド |
抗cd47抗体、活性化可能抗cd47抗体、およびその使用方法
|
|
JP7592712B2
(ja)
*
|
2019-11-06 |
2024-12-02 |
システィミューン, インク. |
ガイダンス及びナビゲーションコントロールタンパク質、その製造方法及び使用方法
|
|
MX2022005666A
(es)
|
2019-11-14 |
2022-10-07 |
Werewolf Therapeutics Inc |
Polipeptidos de citocina activables y metodos de uso de los mismos.
|
|
CN115666704B
(zh)
|
2019-12-13 |
2025-09-26 |
比特比德科有限责任公司 |
用于将治疗剂递送至胃肠道的可摄取装置
|
|
CN114945597A
(zh)
*
|
2020-01-17 |
2022-08-26 |
艾提欧生物疗法有限公司 |
降低脱靶毒性的前抗体
|
|
JP7789002B2
(ja)
|
2020-01-29 |
2025-12-19 |
インヒブルクス バイオサイエンシズ インコーポレイテッド |
Cd28シングルドメイン抗体ならびにその多価および多重特異性の構築物
|
|
TWI888487B
(zh)
*
|
2020-02-14 |
2025-07-01 |
日商協和麒麟股份有限公司 |
與cd3結合之雙特異性抗體
|
|
WO2021178253A1
(en)
*
|
2020-03-03 |
2021-09-10 |
Systimmune, Inc. |
Anti-cd19 antibodies and methods of using and making thereof
|
|
TWI908779B
(zh)
*
|
2020-03-17 |
2025-12-21 |
美商西雅圖免疫公司 |
引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法
|
|
MX2023013382A
(es)
|
2020-04-04 |
2024-01-30 |
Janux Therapeutics Inc |
Composiciones y metodos relacionados con anticuerpos activados contra tumores dirigidos a egfr y antigenos de celulas efectoras.
|
|
JP2023521384A
(ja)
|
2020-04-09 |
2023-05-24 |
シートムエックス セラピューティクス,インコーポレイテッド |
活性化可能抗体を含む組成物
|
|
IL297601A
(en)
|
2020-04-29 |
2022-12-01 |
Teneobio Inc |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
|
CN116096754A
(zh)
*
|
2020-05-04 |
2023-05-09 |
免疫里森公司 |
前体三特异性抗体构建体及其使用方法
|
|
EP4631977A3
(en)
|
2020-08-11 |
2025-12-10 |
Janux Therapeutics, Inc. |
Cleavable linker compositions and methods
|
|
CA3192204A1
(en)
|
2020-08-19 |
2022-02-24 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
|
WO2022046658A1
(en)
*
|
2020-08-24 |
2022-03-03 |
Janux Therapeutics, Inc. |
Antibodies targeting trop2 and cd3 and uses thereof
|
|
JP7518286B2
(ja)
|
2020-08-25 |
2024-07-17 |
ギリアード サイエンシーズ, インコーポレイテッド |
Hivを標的とする多重特異性抗原結合分子及び使用方法
|
|
US12116411B2
(en)
*
|
2020-11-03 |
2024-10-15 |
Abzyme Therapeutics Llc |
Antibodies binding to human CD3 at acidic pH
|
|
JP7716473B2
(ja)
|
2020-11-04 |
2025-07-31 |
ジェネンテック, インコーポレイテッド |
抗cd20/抗cd3二重特異性抗体の皮下投薬
|
|
AU2021374594B2
(en)
|
2020-11-04 |
2026-03-05 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
|
TWI874719B
(zh)
|
2020-11-04 |
2025-03-01 |
美商建南德克公司 |
用抗cd20/抗cd3雙特異性抗體進行治療之給藥
|
|
EP4245317A4
(en)
*
|
2020-11-10 |
2024-11-06 |
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. |
BISPECIFIC ANTIBODY FOR CLAUDIN 18A2 AND CD3 AND APPLICATION OF BISPECIFIC ANTIBODY
|
|
WO2022115865A2
(en)
*
|
2020-11-25 |
2022-06-02 |
Xilio Development, Inc. |
Tumor-specific cleavable linkers
|
|
US20240043536A1
(en)
*
|
2020-12-08 |
2024-02-08 |
Janux Therapeutics, Inc. |
Peptide compositions and methods for anti-cd3 binding domains
|
|
AU2021396172A1
(en)
|
2020-12-09 |
2023-07-06 |
Janux Therapeutics, Inc. |
Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
|
|
EP4274617A4
(en)
*
|
2021-01-05 |
2025-04-02 |
Musc Foundation for Research Development |
A BISPECIFIC AGR2XCD3 ENGAGER FOR THE TREATMENT OF CANCER
|
|
WO2022170619A1
(en)
*
|
2021-02-11 |
2022-08-18 |
Adagene Pte. Ltd. |
Anti-cd3 antibodies and methods of use thereof
|
|
KR102671734B1
(ko)
*
|
2021-04-13 |
2024-06-04 |
건국대학교 글로컬산학협력단 |
개과 동물의 CD3ε 특이적 항체 또는 그의 항원 결합 단편
|
|
CA3213632A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
TW202244059A
(zh)
|
2021-04-30 |
2022-11-16 |
瑞士商赫孚孟拉羅股份公司 |
用抗cd20/抗cd3雙特異性抗體進行治療之給藥
|
|
EP4337330A1
(en)
|
2021-05-14 |
2024-03-20 |
Genentech, Inc. |
Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
US20240279351A1
(en)
*
|
2021-06-16 |
2024-08-22 |
Regents Of The University Of Minnesota |
Targeted adam17 blocker compounds, anti-adam17 antibodies, methods of making, and methods of using
|
|
EP4359443A4
(en)
*
|
2021-06-25 |
2026-02-25 |
Harpoon Therapeutics Inc |
Sustained-release immune cell contact proteins and processing methods
|
|
AU2022333089A1
(en)
*
|
2021-08-25 |
2024-02-29 |
Systimmune, Inc. |
Bispecific tetravalent antibody targeting egfr and her3
|
|
WO2023051727A1
(zh)
*
|
2021-09-30 |
2023-04-06 |
上海君实生物医药科技股份有限公司 |
结合cd3的抗体及其用途
|
|
WO2023064955A1
(en)
|
2021-10-15 |
2023-04-20 |
Cytomx Therapeutics, Inc. |
Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
|
|
US20230174995A1
(en)
|
2021-10-15 |
2023-06-08 |
Cytomx Therapeutics, Inc. |
Activatable polypeptide complex
|
|
KR20240115809A
(ko)
|
2021-10-15 |
2024-07-26 |
싸이톰스 테라퓨틱스, 인크. |
활성화 가능한 폴리펩타이드 복합체
|
|
IL312728A
(en)
|
2021-11-30 |
2024-07-01 |
Daiichi Sankyo Co Ltd |
Protease-cleavable masked antibodies
|
|
CN118401555A
(zh)
*
|
2021-12-09 |
2024-07-26 |
信华生物药业(广州)有限公司 |
抗体掩蔽物及其用途
|
|
US12269887B2
(en)
|
2022-01-20 |
2025-04-08 |
Regents Of The University Of Minnesota |
Anti-canine CD16 polypeptides, anti-canine CD64 polypeptides, compositions including same, and methods of using
|
|
TW202342106A
(zh)
|
2022-02-09 |
2023-11-01 |
日商第一三共股份有限公司 |
環境應答性遮蔽抗體及其利用
|
|
US12365743B2
(en)
|
2022-02-23 |
2025-07-22 |
Xencor, Inc. |
Anti-CD28 x anti-PSMA antibodies
|
|
AU2023226005A1
(en)
|
2022-02-23 |
2024-08-29 |
Bright Peak Therapeutics Ag |
Activatable il-18 polypeptides
|
|
MX2024011468A
(es)
|
2022-03-23 |
2024-09-25 |
Hoffmann La Roche |
Tratamiento conjunto de un anticuerpo biespecifico anti-cd20/anti-cd3 y quimioterapia.
|
|
US20250333539A1
(en)
|
2022-03-23 |
2025-10-30 |
Cytomx Therapeutics, Inc. |
Activatable antigen-binding protein constructs and uses of the same
|
|
JP2025512798A
(ja)
|
2022-03-25 |
2025-04-22 |
サイトムエックス セラピューティクス,インク. |
活性化可能な二重アンカー型マスク化分子及びその使用方法
|
|
WO2023192973A1
(en)
|
2022-04-01 |
2023-10-05 |
Cytomx Therapeutics, Inc. |
Activatable multispecific molecules and methods of use thereof
|
|
EP4504782A2
(en)
|
2022-04-01 |
2025-02-12 |
CytomX Therapeutics, Inc. |
Cd3-binding proteins and methods of use thereof
|
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
|
US20230406927A1
(en)
*
|
2022-04-29 |
2023-12-21 |
Regents Of The University Of Minnesota |
Masked single-domain antibodies and methods thereof
|
|
JP2025525867A
(ja)
|
2022-08-01 |
2025-08-07 |
サイトムエックス セラピューティクス,インク. |
プロテアーゼ切断性部分及びその使用方法
|
|
JP2025525868A
(ja)
|
2022-08-01 |
2025-08-07 |
サイトムエックス セラピューティクス,インク. |
プロテアーゼ切断性部分及びその使用方法
|
|
EP4565250A1
(en)
|
2022-08-01 |
2025-06-11 |
CytomX Therapeutics, Inc. |
Protease-cleavable substrates and methods of use thereof
|
|
AR130078A1
(es)
|
2022-08-01 |
2024-10-30 |
Cytomx Therapeutics Inc |
Substratos escindibles por proteasas, y métodos de uso de los mismos
|
|
JP2025525880A
(ja)
|
2022-08-01 |
2025-08-07 |
サイトムエックス セラピューティクス,インク. |
プロテアーゼ切断性部分及びその使用方法
|
|
GB202214132D0
(en)
*
|
2022-09-27 |
2022-11-09 |
Coding Bio Ltd |
CLL1 binding molecules
|
|
WO2024088987A1
(en)
|
2022-10-26 |
2024-05-02 |
F. Hoffmann-La Roche Ag |
Combination therapy for the treatment of cancer
|
|
EP4615514A2
(en)
*
|
2022-11-10 |
2025-09-17 |
Janux Therapeutics, Inc. |
Antibodies targeting egfr and cd3 and uses thereof
|
|
US20240376170A1
(en)
|
2023-01-11 |
2024-11-14 |
Bright Peak Therapeutics Ag |
Conditionally activated proteins and methods of use
|
|
US20240417436A1
(en)
|
2023-01-11 |
2024-12-19 |
Bright Peak Therapeutics Ag |
Conditionally activated immunocytokines and methods of use
|
|
EP4695281A1
(en)
|
2023-04-12 |
2026-02-18 |
CytomX Therapeutics, Inc. |
Masking polypeptides, activatable cytokine constructs, and related compositions and methods
|
|
CN120936384A
(zh)
|
2023-04-12 |
2025-11-11 |
西托姆克斯治疗公司 |
掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法
|
|
WO2024216170A2
(en)
|
2023-04-12 |
2024-10-17 |
Cytomx Therapeutics, Inc. |
Activatable cytokine constructs and related compositions and methods
|
|
WO2024218164A1
(en)
|
2023-04-17 |
2024-10-24 |
Synaffix B.V. |
Stable 4-isoxazoline conjugates
|
|
WO2024243093A2
(en)
*
|
2023-05-19 |
2024-11-28 |
The Regents Of The University Of California |
Multispecific antibodies targeting cd3 and cd22
|
|
WO2025038668A1
(en)
|
2023-08-14 |
2025-02-20 |
Voro Therapeutics, Inc. |
Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
|
|
WO2025041101A1
(en)
|
2023-08-23 |
2025-02-27 |
Bright Peak Therapeutics Ag |
Activatable il-18 immunocytokines and uses thereof
|
|
CN121729430A
(zh)
*
|
2023-10-11 |
2026-03-24 |
合肥安博宁生命科技有限公司 |
抗cd3可激活抗体及其用途
|
|
WO2025201240A1
(en)
*
|
2024-03-25 |
2025-10-02 |
Tavotek Biotherapeutics (Hong Kong) Limited |
Antibodies targeting cd3, cd28, and pd-l1 and uses thereof
|
|
WO2025230233A1
(ko)
*
|
2024-05-03 |
2025-11-06 |
국민대학교산학협력단 |
인간 cd3에 특이적인 항체 및 이의 용도
|
|
WO2025235515A1
(en)
|
2024-05-07 |
2025-11-13 |
Cytomx Therapeutics, Inc. |
Activatable polypeptide complex formulations
|
|
WO2025240659A2
(en)
|
2024-05-14 |
2025-11-20 |
Cytomx Therapeutics, Inc. |
Activatable constructs, compositions and methods
|
|
WO2026006492A2
(en)
|
2024-06-25 |
2026-01-02 |
Ypsilon Therapeutics, Inc. |
Anti-prame/hla-a2 antibodies and uses thereof
|
|
WO2026006495A1
(en)
|
2024-06-25 |
2026-01-02 |
Alloy Therapeutics, Inc. |
Anti-wt1/hla-a2 antibody and uses thereof
|
|
WO2026020161A1
(en)
|
2024-07-19 |
2026-01-22 |
Cytomx Therapeutics, Inc. |
Activatable il-12 constructs and related compositions and methods
|
|
WO2026024841A1
(en)
|
2024-07-24 |
2026-01-29 |
Astellas Us Llc |
Bispecific antibodies that bind cd3 and muc1 and methods of use thereof
|
|
WO2026035650A2
(en)
|
2024-08-05 |
2026-02-12 |
Cytomx Therapeutics, Inc. |
Cleavable polypeptides and methods of use thereof
|
|
WO2026052652A1
(en)
*
|
2024-09-03 |
2026-03-12 |
F. Hoffmann-La Roche Ag |
Cytokine receptor agonist
|
|
WO2026052654A1
(en)
*
|
2024-09-03 |
2026-03-12 |
F. Hoffmann-La Roche Ag |
Cytokine receptor agonist
|
|
WO2026083296A1
(en)
|
2024-10-16 |
2026-04-23 |
Bright Peak Therapeutics Ag |
Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains
|
|
WO2026083295A1
(en)
|
2024-10-16 |
2026-04-23 |
Bright Peak Therapeutics Ag |
Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains
|